Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.61 |
| ▸ | CA2 | P00918 | 6/20 | 0.61 |
| ▸ | CA12 | O43570 | 5/20 | 0.61 |
| ▸ | CA9 | Q16790 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | SUCNR1 | Q9BXA5 | 4/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910539 | 0.90 | CA1 (0.62) | CA1CA2CA12CA9ITGB3 | |
| SCHEMBL15032923 | 0.90 | CA1 (0.59) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL17366464 | 0.89 | CA12 (0.59) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL17809681 | 0.88 | CA1 (0.53) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL17809675 | 0.88 | CA1 (0.53) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL16627553 | 0.88 | CA1 (0.53) | CA1CA2CA12CA9ITGB3 | |
| SCHEMBL10110731 | 0.88 | CA1 (0.55) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL16808348 | 0.87 | CA1 (0.55) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL16383779 | 0.86 | CA1 (0.57) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL16344311 | 0.86 | CA1 (0.57) | CA1CA2CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241528-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-10167266-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-8846688-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8227474-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8198286-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1485360-B1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-1485360-A4 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060142306-A1 | Bronchodilator agents; respiratory system disorders; skin disorders ; asthma; hypotensive agents | CYFI, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-6858615-B2 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; 2,6-diaminopyrazine derivatives | PARION SCIENCES, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1485360-A2 | SODIUM CHANNEL BLOCKERS | Johnson, Michael R. (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040229884-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; long half-life on mucosal surfaces; pyrazinoylguanidine derivatives | PARION SCIENCES, INC. | 2004-11-18 | — | — | US | disclosed |
| US-20040204425-A1 | Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for therapy of chronic bronchitis, emphysema, cystic fibrosis, and eye disorders | PARION SCIENCES, INC. (US) | 2004-10-14 | — | — | US | disclosed |
| US-20040198749-A1 | Broncholdilator agents; hydration of mucous membranes; respiratory system disorders | PARION SCIENCES, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20040198748-A1 | Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders | PARION SCIENCES, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20030199456-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; 2,6-diaminopyrazine derivatives | CYFI, INC. (US) | 2003-10-23 | — | — | US | disclosed |
| WO-2003070182-A2 | SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CA1 873/4885CA2 162/4885CA12 835/4885 |
| US-10167266-B2 | Sodium channel blockers | SCNN1B, SCNN1A, SCNN1G | CA1 656/4885CA2 203/4885CA12 610/4885 |
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CA1 873/4885CA2 162/4885CA12 835/4885 |
| US-20040229884-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; long half-life on mucosal surfaces; pyrazinoylguanidine derivatives | SCNN1B, KCNN2, SCNN1G | CA1 1704/4885CA2 180/4885CA12 1375/4885 |
| US-20060142306-A1 | Bronchodilator agents; respiratory system disorders; skin disorders ; asthma; hypotensive agents | ADRB2, ADRB3, ADRA1D | CA1 3670/4885CA2 138/4885CA12 1619/4885 |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CA1 873/4885CA2 162/4885CA12 835/4885 |
| US-20040204425-A1 | Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for therapy of chronic bronchitis, emphysema, cystic fibrosis, and eye disorders | CFTR, TRPC4, TRPC5 | CA1 3242/4885CA2 106/4885CA12 1640/4885 |
| US-20040198749-A1 | Broncholdilator agents; hydration of mucous membranes; respiratory system disorders | AQP1, TRPV1, AQP3 | CA1 1050/4885CA2 101/4885CA12 483/4885 |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CA1 873/4885CA2 162/4885CA12 835/4885 |
| US-20030199456-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; 2,6-diaminopyrazine derivatives | SCNN1B, KCNN2, KCNN1 | CA1 1127/4885CA2 148/4885CA12 721/4885 |
| US-20040198748-A1 | Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders | HRH4, HRH2, HRH1 | CA1 1175/4885CA2 384/4885CA12 1543/4885 |
| US-20190241528-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CA1 873/4885CA2 162/4885CA12 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.